Aligos Therapeutics, Inc. - ALGS
About Gravity Analytica
Recent News
- 12.11.2025 - Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
- 12.10.2025 - Rapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks
- 12.09.2025 - An antisense oligonucleotide strategy targeting the Hepatitis Delta Virus
- 12.09.2025 - Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
- 12.09.2025 - Explorations Towards the Selection of a Potential Best-in-Class HBV ASO
- 11.21.2025 - A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants
- 11.09.2025 - Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not -treated Subjects with Chronic HBV
- 11.07.2025 - CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In Vitro
- 11.07.2025 - Lead Optimization and Selection of a Potential Best-in-Class HBV ASO
- 11.07.2025 - Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence time